

EBMT Centre Identification Code (CIC):	Treatment Type	Other	
Hospital Unique Patient Number (UPN):			
Patient Number in EBMT Registry:	Treatment Date		(YYYY/MM/DD)

TREATMENT NON – HCT/CT/GT/IST

(Malignant disorders only)

HCT/C	CT/GT-related form		n (conditioning/lymphodepletion It for GvHD and complications :			
	led dataset. treatment started	:/_	_			
Diagr	nosis for which th	is treatmer	nt was given:			
A line	of treatment: of treatment cove disease status of	rs all cycles	nber) of the same drugs/regimen giv	ven in the sa	me period with the	same reason, and within the
Reas	on for this line of	treatment:				
	Induction	☐ Maintei	nance / preventive treatment:	Type of re	apse prevention:	MRD negative
	Bridging	☐ Consol	idation			☐ MRD positive
	Relapse	Other;	specify:			☐ MRD unknown
			CHEMOTHERAPY / D	RUG REG	IMEN	
Chem	otherapy/Drugs:	☐ No	Yes Unknown			
	f patient received Do not report each		rapyldrugs: end date separately)			
			YYYY/MM/DD)	nent)		
Т	reatment stopped	d: □ No				
		☐ Yes;	End date:I (Y		· —	ent)
			Reason for treatment withdr		☐ Planned witho	drawal
			(for Chronic Lymphocytic Leuk	kaemia only)	☐ Toxicity	
						or insufficient response
					_	; specify
					Unknown	
		☐ Unkno	own			
	Chemo/Drug regir	men*:		_		
•	Chemo/Drug regii	men*:				
	Chemo/Drug regir	men*:				
	Chemo/Drug regii	men*:				

Copy and fill-in this page (chemotherapy / drug regimen) as often as necessary within the same line of treatment.

^{*}Please consult the **LIST OF CHEMOTHERAPY DRUGS/AGENTS AND REGIMENS** on the EBMT website for drugs/regimens names.



EBMT Centre Identification Code (CIC): Hospital Unique Patient Number (UPN):	Treatment Type	
Patient Number in EBMT Registry:	Treatment Date / _ / _ (YYYY/MM/DD)	

INTERVENTIONS	
Radiotherapy: No Yes Unknown	
If patient received radiotherapy incl. irradiation: Start date: I (YYYY/MM/DD) Unknown	
Treatment stopped: ☐ No ☐ Yes; End date: I (YYYY/MM/DD) ☐ Unknown ☐ Unknown	
Splenic irradiation: No Yes Unknown (for Myeloproliferative neoplasms only) If patient received splenic irradiation: Total prescribed radiation dose as per protocol: Gy Unknown	
Number of fractions: Unknown	
Number of radiation days: Unknown	
Surgery: No Yes Unknown	
If patient underwent surgery: Date: I _ (YYYY/MM/DD) Unknown	
Surgery type: Splenectomy Other; specify Unknown Copy and fill-in this section as often as necessary within the same line of treatments	nt.
RESPONSE TO THIS LINE OF TREATMENT (Disease Specific)	
Complete only one section with the main indication diagnosis for which treatment was given. Response assessment date: / _ / _ (YYYY/MM/DD)	
ACUTE LEUKAEMIAS	Go to page 3
CHRONIC LEUKAEMIAS	Go to page 3
PLASMA CELL NEOPLASMS (PCN)	Go to page 3
MYELOPROLIFERATIVE NEOPLASMS (MPN)	Go to page 4
MYELODYSPLASTIC NEOPLASMS (MDS), MDS / MPN OVERLAP SYNDROMES	Go to page 4
LYMPHOMAS	Go to page 4
SOLID TUMOURS	Go to page 4
BONE MARROW FAILURE SYNDROMES (BMF) including APLASTIC ANAEMIA (AA)	Go to page 5
AUTOIMMUNE DISORDERS	Go to page 5
OTHER DIAGNOSIS	Go to page 5



EBMT Centre Identification Code (CIC):	Treatment Type	Other	
Hospital Unique Patient Number (UPN):			
Patient Number in EBMT Registry:	Treatment Date _	///	_(YYYY/MM/DD)

RESPONSE TO THIS LINE OF TREATMENT

Complete only one section with the main indication diagnosis for which treatment was given.	
Acute leukaemias (AML, PLN, Other)	
Complete remission (CR)	
☐ Not in complete remission	
☐ Unknown	
☐ Not evaluated	
Chronic leukaemias (CML, CLL, PLL, Other)	
Chronic Myeloid Leukaemia (CML):	
Chronic phase (CP); Number: 1st 2nd 3rd or higher Unknown	
Haematological remission: No Yes Not evaluated Unknown	
Cytogenetic remission: No Yes Not evaluated Unknown	
Molecular remission: ☐ No ☐ Yes ☐ Not evaluated ☐ Unknown	
☐ Accelerated phase; Number : ☐ 1 st ☐ 2 nd ☐ 3 rd or higher ☐ Unknown	
☐ Blast crisis; Number : ☐ 1 st ☐ 2 nd ☐ 3 rd or higher ☐ Unknown	
Unknown	
☐ Not evaluated	
Chronic Lymphocytic Leukaemia (CLL), Prolymphocytic Leukaemia (PLL) and other chronic leukaemias:	
Complete remission (CR)	
Partial remission (PR)	
Progression: Resistant to last regimen Sensitive to last regimen Unknown	
Stable disease (no change, no response/loss of response)	
Unknown	
☐ Not evaluated	
Plasma cell neoplasms (PCN)	
☐ Complete remission (CR) Number: ☐ 1st	
Stringent complete remission (sCR)	
☐ Very good partial remission (VGPR) ☐ 3rd or higher	
Partial remission (PR)	
☐ Relapse	
☐ Progression	
☐ Stable disease (no change, no response/loss of response)	
Unknown	
☐ Not evaluated	

For AL, CLL and PCN proceed to next page



EBMT Centre Identification Code (CIC):	Treatment Type	☐ Other	
Hospital Unique Patient Number (UPN):			
Patient Number in EBMT Registry:	Treatment Date	1 1	(YYYY/MM/DD)

RESPONSE TO THIS LINE OF TREATMENT

Complete only for AL, CLL and PCN	
eukaemias (AL, CLL) and PCN	(complete only for patient in CR or sCR)
Minimal residual disease (MRD): Negative Positive Not evaluated Unknown	
Date MRD status evaluated:	//(<i>YYYY/MM/DD</i>)
Sensitivity of MRD assay:	Method used: (select all that apply) PCR Flow cytometry NGS Other; specify: Unknown
	n indication diagnosis for which treatment was given. Number: 1st
yeloproliferative neoplasms (MPN	, Myelodysplastic neoplasms (MDS), MDS/MPN overlap syndromes
yeloproliferative neoplasms (MPN	Number: 1st 2nd 3rd or higher
yeloproliferative neoplasms (MPN	Number: 1st 2nd 3rd or higher Unknown
yeloproliferative neoplasms (MPN	Number: 1st 2nd 3rd or higher Unknown
yeloproliferative neoplasms (MPN Complete remission (CR) Improvement but no CR Primary refractory phase (no complete remission)	Number: 1st 2nd 3rd or higher Unknown 1st 2nd 2nd 3rd or higher 2nd 3rd or higher 3rd or higher
yeloproliferative neoplasms (MPN Complete remission (CR) Improvement but no CR Primary refractory phase (no complete remission) Relapse	Number: 1st 2nd 3rd or higher Unknown 1st 2nd 2nd 3rd or higher 2nd 3rd or higher 3rd or higher

Treatment_for_diagnosis_v1.0 4 of 5 2024-06-04



EBMT Centre Identification Code (CIC):	Treatment Type 🔲 Other
Hospital Unique Patient Number (UPN):	
Patient Number in EBMT Registry:	Treatment Date / _ / _ (YYYY/MM/DD)

RESPONSE TO THIS LINE OF TREATMENT continued

Complete only one section with the main indication diagnosis for which treatment was given.

Lymphomas
Chemorefractory relapse or progression, including primary refractory disease
☐ Complete remission (CR): ☐ Confirmed ☐ Unconfirmed (CRU*) ☐ Unknown
Partial remission (PR)
☐ Stable disease (no change, no response/loss of response)
☐ Untreated relapse (from a previous CR) or progression (from a previous PR)
☐ Unknown
☐ Not evaluated
* CRU: Complete response with persistent scan abnormalities of unknown significance
Solid tumours
☐ Complete remission (CR): ☐ Confirmed ☐ Unconfirmed ☐ Unknown
First Partial remission
☐ Partial remission (PR)
☐ Progressive disease
☐ Relapse: ☐ Resistant ☐ Sensitive ☐ Unknown
☐ Stable disease (no change, no response/loss of response)
☐ Unknown
☐ Not evaluated
Other diagnosis
☐ No evidence of disease
☐ Improved
□ No response
□ Worse
☐ Unknown
☐ Not evaluated